Philips has now developed a device intended to integrate two forms of laser-based PAD therapy, atherectomy and intravascular ...

Heart disease is expected to affect 61% of US adults by 2050, so it’s important to know when problems may be afoot.

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

Learn about Peripheral Artery Disease (PAD) and its impact on the Black community. Discover the risks, symptoms, and treatment options for this irreversible medical condition.

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Johnson & Johnson MedTech's Shockwave Medical unit today announced the first clinical outcomes associated with its Javelin ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

This is the first hospital in North Texas to offer the treatment for patients suffering from complex peripheral artery ...

Netherlands-based diagnostics imaging company Royal Philips announced the enrolment of its first patient in the US THRO IDE ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...